<Layman>
Case Summary - Diana Layman
[[Federal Register: June 25, 2007 (Volume 72, Number 121)]
[Notices]
[Page 34690]
From the Federal Register Online via GPO Access
[wais.access.gpo.gov]
[DOCID:fr25jn07-70]
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Office of the Secretary
Findings of Scientific Misconduct
ACTION: Notice.
SUMMARY: Notice is hereby given that the Office of Research Integrity
(ORI) and the Assistant Secretary for Health have taken final action in
the following case:
Diana Layman, University of Oklahoma Health Sciences Center: Based
on the report of an investigation conducted by the University of
Oklahoma Health Sciences Center (OUHSC) and additional analysis
conducted by the Office of Research Integrity during its oversight
review, the U.S. Public Health Service (PHS) found that Ms. Diana
Layman, Tribal Efforts Against Lead (TEAL) phlebotomist, OUHSC, engaged
in scientific misconduct in research supported by National Institute of
Environmental Health Sciences (NIEHS), National Institutes of Health
(NIH), grant R01 ES008755.
Specifically, Ms. Layman falsified research in the TEAL study by
substituting or conspiring with another phlebotomist to substitute her
blood or blood of another phlebotomist for blood samples of 10-15 child
participants in the TEAL study.
Ms. Layman has entered into a Voluntary
Exclusion Agreement (Agreement) in which she has voluntarily agreed,
for a period of three (3) years, beginning on May 30, 2007:
(1) To exclude herself from any contracting or subcontracting with
any agency of the United States Government and from eligibility or
involvement in nonprocurement programs of the United States Government
as defined in HHS' implementation of OMB Guidelines to Agencies on
Governmentwide Debarment and Suspension at 2 CFR part 376, et seq.; and
(2) To exclude herself from serving in any advisory capacity to
PHS, including but not limited to service on any PHS advisory
committee, board, and/or peer review committee, or as a consultant.
FOR FURTHER INFORMATION CONTACT:
Director, Division of Investigative Oversight
Office of Research Integrity
1101 Wootton Parkway, Suite 750,
Rockville, MD 20852
(240) 453-8800
John Dahlberg
Acting Director
Office of Research Integrity
|
Assurance
